A child with gemcitabine-induced severe radiation recall myositis resulting in a compartment syndrome

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 2, 2013, Pages 156-161

  Eckardt, Mark A ^a,b   Bean, Adrienne ^c   Selch, Michael T ^b   Federman, Noah ^b,d  

^a Division of Hematology Oncology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Department of Diagnostic Radiology ^*  (United States)

^d MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

child; compartment syndrome; docetaxel; gemcitabine; myositis; radiation recall; synovial sarcoma

Indexed keywords

DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE;

ADOLESCENT; ARM PAIN; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COMPARTMENT SYNDROME; CYTOGENETICS; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE RESECTION; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL EDEMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION RECALL; RADIATION RESPONSE; SYNOVIAL SARCOMA; TUMOR VOLUME;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; COMPARTMENT SYNDROMES; DEOXYCYTIDINE; FEMALE; HUMANS; RADIODERMATITIS; SARCOMA, SYNOVIAL;

EID: 84874467744     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31827e4c28     Document Type: Article

References (43)

1. D'Angio GJ, Farber S, Maddock CL. Potentiation of x-ray effects by actinomycin D. Radiology. 1959;73:175-177.
2. Friedlander PA, Bansal R, Schwartz L, et al. Gemcitabine-related radiation recall preferentially involves internal tissue and organs. Cancer. 2004;100:1793-1799.
3. O'Regan KN, Nishino M, Armand P, et al. Sonographic features of pectoralis muscle necrosis secondary to gemcita-bine-induced radiation recall: case report and review of current literature. J Ultrasound Med. 2010;29:1499-1502.
4. Vogl DT, Glatstein E, Carver JR, et al. Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leuk Lymphoma. 2005;46:1313-1320.
5. Tan DHS, Bunce PE, Liles WC, et al. Gemcitabine-related "pseudocellulitis": report of 2 cases and review of the literature. Clin Infect Dis. 2007;45:e72-e76.
6. Burris HA III, Hurtig J. Radiation recall with anticancer agents. Oncologist. 2010;15:1227-1237.
7. Cole PD, Schwartz CL, Drachtman RA, et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report. J Clin Oncol. 2009;27:1456-1461.
8. Balogh ZJ, Butcher NE. Compartment syndromes from head to toe. Crit Care Med. 2010;38:S445-S451.
9. Grottkau B, Epps H, Discala C. Compartment syndrome in children and adolescents. J Pediatr Surg. 2005;40: 678-682.
10. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994;12:1535-1540.
11. Welsh JS, Torre TG, DeWeese TL, et al. Radiation myositis. Ann Oncol. 1999;10:1105-1108.
12. Burstein HJ. Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol. 2000;18: 693-694.
13. Castellano D, Hitt R, Cortes-Funes H, et al. Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine. J Clin Oncol. 2000;18:695-696.
14. Ganem G, Solal-Celigny P, Joffroy A, et al. Radiation myositis: the possible role of gemcitabine. Ann Oncol. 2000;11:1615-1616.
15. Sole Monne JM, Macia Garau M, Cambra Serest MJ, et al. 35 radiation recall dermatitis from gemcitabine. A new toxic effect in 3 patients. Radiother Oncol. 2000;57:S32-S34.
16. Bar-Sela G, Beny A, Bergman R, et al. Gemcitabine-induced radiation recall dermatitis: case report. Tumori. 2001;87: 428-430.
17. Fogarty G, Ball D, Rischin D. Radiation recall reaction following gemcitabine. Lung Cancer. 2001;33:299-302.
18. Jeter MD, Janne PA, Brooks S, et al. Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002;53: 394-400.
19. Schwartz BM, Khuntia D, Kennedy AW, et al. Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy. Gynecol Oncol. 2003;91:421-422.
20. Marisavljevic D, Ristic B, Hajder J. Gemcitabine-induced radiation recall dermatitis in a patient with resistant Hodgkin lymphoma. Am J Hematol. 2005;80:91.
21. Barlesi F, Tummino C, Tasei AM, et al. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis. Lung Cancer. 2006;54:423-425.
22. Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7:51-58.
23. Fakih MG. Gemcitabine-induced rectus abdominus radiation recall. JOP. 2006;7:306-310.
24. Horan G, Smith SL, Podd TJ. Gemcitabine-induced radiation necrosis of the pectoralis major muscle. Clin Oncol (R Coll Radiol). 2006;18:85.
25. Pinson PJ, Griep C, Sanders WH, et al. Myositis as a "radiation- recall phenomenon" following palliative chemotherapy with carboplatin-gemcitabin for non-small-cell pulmonary carcinoma. Ned Tijdschr Geneeskd. 2006;150: 1891-1894.
26. Saif MW, Sellers S, Russo S. Gemcitabine-related radiation recall in a patient with pancreatic cancer. Anticancer Drugs. 2006;17:107-111.
27. Squire S, Chan M, Feller E, et al. An unusual case of gemcitabine-induced radiation recall. Am J Clin Oncol. 2006;29:636.
28. Schwarte S, Wagner K, Karstens JH, et al. Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol. 2007;183:215-217.
29. Hird AE, Wilson J, Symons S, et al. Radiation recall dermatitis: case report and review of the literature. Curr Oncol. 2008;15:53-62.
30. Alco G, Igdem S, Dincer M, et al. Gemcitabine induced radiation recall myositis: report of two cases. Uhod-Uluslar Hematol. 2009;19:249-253.
31. Zainon WMNW, Borg M, Higgs B, et al. Gemcitabine-induced radiation recall in the treatment of pancreatic cancer. Asia Pac J Clin Oncol. 2009;5:17-23.
32. Kodym E, Kalinska R, Ehringfeld C, et al. Frequency of radiation recall dermatitis in adult cancer patients. Onkologie. 2005;28:18-21.
33. Haffty BG, Vicini FA, Beitsch P, et al. Timing of chemotherapy after mammosite radiation therapy system breast brachytherapy: analysis of the american society of breast surgeons mammosite breast brachytherapy registry trial. Int J Radiat Oncol Biol Phys. 2008;72:1441-1448.
34. Saif MW, Black G, Johnson M, et al. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemother Pharmacol. 2006;58:771-775.
35. Yeo W, Johnson PJ. Radiation-recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence, and management. Am J Clin Dermatol. 2000;1:113-116.
36. Mizumoto M, Harada H, Asakura H, et al. Frequency and characteristics of docetaxel-induced radiation recall phenomenon. Int J Radiat Oncol Biol Phys. 2006;66:1187-1191.
37. Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol. 2001;59:237-245.
38. Kitani H, Kosaka T, Fujihara T, et al. The "recall effect" in radiotherapy: is subeffective, reparable damage involved? Int J Radiat Oncol Biol Phys. 1990;18:689-695.
39. Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev. 2005;31:555-570.
40. Brandes A, Reichmann U, Plasswilm L, et al. Time-and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine-a report of three cases. Anticancer Drugs. 2000;11:15-17.
41. Kuku I, Kaya E, Sevinc A, et al. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothe-lioma. J Eur Acad Dermatol Venereol. 2002;16:271-272.
42. Badger J, Kang S, Uzieblo A, et al. Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: case 3. Photo therapy recall with gemcitabine following ultraviolet B treatment. J Clin Oncol. 2005;23:7224-7225.
43. Eckardt JJ, Eilber FR, Grant TT, et al. Management of stage IIB osteogenic sarcoma: experience at the university of california los angeles. Cancer Treat Symp. 1985;3:117-130.